Soluble cytokine receptors in biological therapy.
Due to their fundamental involvement in the pathogenesis of many diseases, cytokines constitute key targets for biotherapeutic approaches. The discovery that soluble forms of cytokine receptors are involved in the endogenous regulation of cytokine activity has prompted substantial interest in their potential application as immunotherapeutic agents. As such, soluble cytokine receptors have many advantages, including specificity, low immunogenicity and high affinity. Potential disadvantages, such as low avidity and short in vivo half-lifes, have been addressed by the use of genetically-designed receptors, hybrid proteins or chemical modifications. The ability of many soluble cytokine receptors to inhibit the binding and biological activity of their ligands makes them very specific cytokine antagonists. Several pharmaceutical companies have generated a number of therapeutic agents based on soluble cytokine receptors and many of them are undergoing clinical trials. The most advanced in terms of clinical development is etanercept (Enbrel, Immunex), a fusion protein between soluble TNF receptor Type II and the Fc region of human IgG1. This TNF-alpha; antagonist was the first soluble cytokine receptor to receive approval for use in humans. In general, most agents based on soluble cytokine receptors have been safe, well-tolerated and have shown only minor side effects in the majority of patients. Soluble cytokine receptors constitute a new generation of therapeutic agents with tremendous potential for applications in a wide variety of human diseases. Two current areas of research are the identification of their most promising applications and characterisation of their long-term effects.
Fernandez-Botran
Rafael
R
Department of Pathology & Laboratory Medicine, School of Medicine, University of Louisville, Louisville, KY 40292, USA. Rafael@louisville.edu
Crespo
Fabian A
FA
Sun
Xichun
X
D001249:Asthma / Q000628:therapy; D001691:Biological Therapy / Q000379:methods*; D016207:Cytokines / Q000037:antagonists & inhibitors; D006801:Humans; D007154:Immune System Diseases / Q000628:therapy; D007167:Immunotherapy / Q000379:methods*; D007249:Inflammation; D011485:Protein Binding; D018121:Receptors, Cytokine / Q000096:biosynthesis* / Q000737:chemistry; D015398:Signal Transduction; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000378:metabolism
D016207:Cytokines; D018121:Receptors, Cytokine; D014409:Tumor Necrosis Factor-alpha